387 related articles for article (PubMed ID: 30027909)
21. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW
J Neurocytol; 2003 Nov; 32(9):1091-105. PubMed ID: 15044841
[TBL] [Abstract][Full Text] [Related]
22. From tau phosphorylation to tau aggregation: what about neuronal death?
Buée L; Troquier L; Burnouf S; Belarbi K; Van der Jeugd A; Ahmed T; Fernandez-Gomez F; Caillierez R; Grosjean ME; Begard S; Barbot B; Demeyer D; Obriot H; Brion I; Buée-Scherrer V; Maurage CA; Balschun D; D'hooge R; Hamdane M; Blum D; Sergeant N
Biochem Soc Trans; 2010 Aug; 38(4):967-72. PubMed ID: 20658986
[TBL] [Abstract][Full Text] [Related]
23. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
[TBL] [Abstract][Full Text] [Related]
24. Sensory Neurons from Tau Transgenic Mice and Their Utility in Drug Screening.
Tolkovsky AM; Brelstaff J
Methods Mol Biol; 2018; 1727():93-105. PubMed ID: 29222775
[TBL] [Abstract][Full Text] [Related]
25. Azure C Targets and Modulates Toxic Tau Oligomers.
Lo Cascio F; Kayed R
ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
[TBL] [Abstract][Full Text] [Related]
26. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
27. Vaccination with Sarkosyl insoluble PHF-tau decrease neurofibrillary tangles formation in aged tau transgenic mouse model: a pilot study.
Ando K; Kabova A; Stygelbout V; Leroy K; Heraud C; Frédérick C; Suain V; Yilmaz Z; Authelet M; Dedecker R; Potier MC; Duyckaerts C; Brion JP
J Alzheimers Dis; 2014; 40 Suppl 1():S135-45. PubMed ID: 24614899
[TBL] [Abstract][Full Text] [Related]
28. Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau.
Klein RL; Lin WL; Dickson DW; Lewis J; Hutton M; Duff K; Meyer EM; King MA
Am J Pathol; 2004 Jan; 164(1):347-53. PubMed ID: 14695347
[TBL] [Abstract][Full Text] [Related]
29. Tauopathies and tau oligomers.
Takashima A
J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
[TBL] [Abstract][Full Text] [Related]
30. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
[TBL] [Abstract][Full Text] [Related]
31. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
32. [Neurofibrillary tangles and early modification of the neuronal cytoskeleton in Alzheimer's disease and in experimental models].
Brion JP
Bull Mem Acad R Med Belg; 1999; 154(6 Pt 2):287-94. PubMed ID: 10992876
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of glob1 suppresses pathogenesis of human neuronal tauopathies in Drosophila by regulating tau phosphorylation and ROS generation.
Nisha ; Sarkar S
Neurochem Int; 2021 Jun; 146():105040. PubMed ID: 33865914
[TBL] [Abstract][Full Text] [Related]
34. Potentiating tangle formation reduces acute toxicity of soluble tau species in the rat.
d'Orange M; Aurégan G; Cheramy D; Gaudin-Guérif M; Lieger S; Guillermier M; Stimmer L; Joséphine C; Hérard AS; Gaillard MC; Petit F; Kiessling MC; Schmitz C; Colin M; Buée L; Panayi F; Diguet E; Brouillet E; Hantraye P; Bemelmans AP; Cambon K
Brain; 2018 Feb; 141(2):535-549. PubMed ID: 29253129
[TBL] [Abstract][Full Text] [Related]
35. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
[TBL] [Abstract][Full Text] [Related]
36. A seeding based cellular assay of tauopathy.
Xu Y; Martini-Stoica H; Zheng H
Mol Neurodegener; 2016 Apr; 11():32. PubMed ID: 27112488
[TBL] [Abstract][Full Text] [Related]
37. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
38. Cellular and regional vulnerability in frontotemporal tauopathies.
Forrest SL; Kril JJ; Halliday GM
Acta Neuropathol; 2019 Nov; 138(5):705-727. PubMed ID: 31203391
[TBL] [Abstract][Full Text] [Related]
39. Degradation or aggregation: the ramifications of post-translational modifications on tau.
Park S; Lee JH; Jeon JH; Lee MJ
BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
[TBL] [Abstract][Full Text] [Related]
40. Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies.
Silva MC; Haggarty SJ
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
